Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

immunization

- PMLiVE

AstraZeneca/Ionis’ Wainzua granted EC approval to treat rare disease ATTRv-PN

ATTRv with polyneuropathy affects up to 40,000 people worldwide

- PMLiVE

DSRU appoints Linda Härmark as director

Härmark is currently deputy director at the Netherlands Pharmacovigilance Centre Lareb

- PMLiVE

NEW WEBINAR! From Clicks to Outcomes: Measuring the Impact of Your Medical Education Platform

Struggling to quantify the value of your medical education platform and prove its ROI? Join our upcoming Pharma-exclusive webinar to learn real-work strategies and tips for developing a Med Ed...

Impetus Digital

- PMLiVE

World Kidney Day – Boehringer launches CKD initiative to tackle UK health inequalities

Approximately 10% of the UK population is affected by chronic kidney disease

Biogen Idec building

Biogen initiates phase 3 study of felzartamab in kidney transplant patients

The trial will evaluate the candidate in patients with antibody-mediated rejection

- PMLiVE

NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis

Around 1,000 patients could benefit from the relugolix combination therapy every year

- PMLiVE

Roche and Zealand partner on mid-stage obesity candidate in deal worth $5.3bn

The companies will develop petrelintide as both a standalone therapy and in combination with Roche’s CT-388

- PMLiVE

Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

The neurological disorder affects more than 150,000 people in the UK

- PMLiVE

Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis

The inflammatory skin disease affects up to 20% of children and 10% of adults worldwide

- PMLiVE

Novartis gains rights to Kyorin’s chronic spontaneous urticaria candidate in deal worth $830m

The common skin condition affects approximately 40 million people worldwide

- PMLiVE

Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA

Over 11,000 people in the UK are affected by the rare genetic disease

- PMLiVE

J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme

More than 125 million people worldwide are estimated to be living with the immune-mediated skin disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links